康复血浆治疗印度成人中度COVID-19:开放标签II期多中心随机对照试验(PLACID试验)
该研究为开放标签、平行组、II期多中心随机对照试验,在印度39家医院纳入464例确诊中度COVID-19成人患者,比较康复血浆联合最佳标准治疗与仅最佳标准治疗的疗效。主要终点为入组后28天内进展为重症或全因死亡,结果显示两组无显著差异,康复血浆未降低进展或死亡风险。
要点
- 康复血浆未降低中度COVID-19患者28天进展为重症或全因死亡的风险。
- 干预组与对照组主要终点发生率分别为19%和18%,风险比1.04(95%CI 0.71-1.54)。
- 该试验在实验室能力有限的实际条件下进行,外推性较高。
核心结论
- 康复血浆治疗与中度COVID-19成人患者进展为重症或全因死亡风险降低无关。
研究设计与样本
- 开放标签、平行组、II期、多中心随机对照试验,在印度39家公立和私立医院开展。
- 纳入464例(≥18岁)确诊中度COVID-19住院成人患者,干预组235例,对照组229例。
- 干预组接受两剂200 mL康复血浆,间隔24小时输注,对照组仅接受最佳标准治疗。
主要发现
- 入组后28天内进展为重症或全因死亡在干预组发生44例(19%),对照组41例(18%)。
- 风险差0.008(95%CI -0.062至0.078),风险比1.04(95%CI 0.71至1.54)。
临床怎么用
- 不推荐将康复血浆常规用于中度COVID-19成人患者以降低疾病进展或死亡风险。
- 在实验室能力有限的实际医疗环境中,该试验结果具有较高外推性。
局限性
- 未预先测量供者和受者的中和抗体存在及水平,仅在研究结束时检测储存样本。
- 开放标签设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India. DESIGN: Open label, parallel arm, phase II, multicentre, randomised controlled trial. SETTING: 39 public and private hospitals across India. PARTICIPANTS: 464 adults (≥18 years) admitted to hospital (screened 22 April to 14 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24/min with oxygen saturation 93% or less on room air): 235 were assigned to convalescent plasma with best standard of care (intervention arm) and 229 to best standard of care only (control arm). INTERVENTIONS: Participants in the intervention arm received two doses of 200 mL convalescent plasma, transfused 24 hours apart. The presence and levels of neutralising antibodies were not measured a priori; stored samples were assayed at the end of the study. MAIN OUTCOME MEASURE: Composite of progression to severe disease (PaO2/FiO2 <100 mm Hg) or all cause mortality at 28 days post-enrolment. RESULTS: Progression to severe disease or all cause mortality at 28 days after enrolment occurred in 44 (19%) participants in the intervention arm and 41 (18%) in the control arm (risk difference 0.008 (95% confidence interval -0.062 to 0.078); risk ratio 1.04, 95% confidence interval 0.71 to 1.54). CONCLUSION: Convalescent plasma was not associated with a reduction in progression to severe covid-19 or all cause mortality. This trial has high generalisability and approximates convalescent plasma use in real life settings with limited laboratory capacity. A priori measurement of neutralising antibody titres in donors and participants might further clarify the role of convalescent plasma in the management of covid-19. TRIAL REGISTRATION: Clinical Trial Registry of India CTRI/2020/04/024775.
引用
- Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020. PMID: 33093056. doi:10.1136/bmj.m3939
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。